Re‐operation due to bleeding (7 days post‐surgery) ‐ not reported · people undergoing definitive fixation of hip, pelvic and long bone fractures
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Myocardial infarction (0 to 30 days) · people undergoing definitive fixation of hip, pelvic and long bone fractures
It is very uncertain whether topical tranexamic acid changes risk of myocardial infarction (30 days post‐surgery) compared with placebo (very low certainty).
1 finding from 1 review
Stroke · people undergoing definitive fixation of hip, pelvic and long bone fractures
It is very uncertain whether topical tranexamic acid changes risk of cerebrovascular accident/stroke (30 days post‐surgery) compared with placebo (very low certainty).
1 finding from 1 review
Deep vein thrombosis · people undergoing definitive fixation of hip, pelvic and long bone fractures
It is very uncertain whether topical tranexamic acid changes risk of deep vein thrombosis (30 days post‐surgery) compared with placebo (very low certainty).
1 finding from 1 review
Risk of suspected serious drug reactions (30 days post‐surgery) · people undergoing definitive fixation of hip, pelvic and long bone fractures
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
All‐cause mortality (30 days post‐surgery) · people undergoing definitive fixation of hip, pelvic and long bone fractures
Intravenous tranexamic acid showed no clear difference in all‐cause mortality (30 days post‐surgery) compared with placebo (low certainty).
1 finding from 1 review
Re‐operation due to bleeding (7 days post‐surgery) ‐ not reported · people undergoing definitive fixation of hip, pelvic and long bone fractures
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Myocardial infarction (0 to 30 days) · people undergoing definitive fixation of hip, pelvic and long bone fractures
Intravenous tranexamic acid showed no clear difference in risk of myocardial infarction (30 days post‐surgery) compared with placebo (low certainty).
1 finding from 1 review
Stroke · people undergoing definitive fixation of hip, pelvic and long bone fractures
Intravenous tranexamic acid showed no clear difference in risk of cerebrovascular accident/stroke (30 days post‐surgery) compared with placebo (low certainty).
1 finding from 1 review
Deep vein thrombosis · people undergoing definitive fixation of hip, pelvic and long bone fractures
It is very uncertain whether intravenous tranexamic acid changes risk of deep vein thrombosis (30 days post‐surgery) compared with placebo (very low certainty).
1 finding from 1 review
Risk of suspected serious drug reactions (30 days post‐surgery) · people undergoing definitive fixation of hip, pelvic and long bone fractures
It is very uncertain whether intravenous tranexamic acid changes risk of suspected serious drug reactions (30 days post‐surgery) compared with placebo (very low certainty).
1 finding from 1 review
Risk of requiring allogeneic blood transfusion (30 days post‐surgery) · people undergoing definitive fixation of hip, pelvic and long bone fractures
It is very uncertain whether topical tranexamic acid changes risk of requiring allogeneic blood transfusion (30 days post‐surgery) compared with placebo (very low certainty).
1 finding from 1 review
All‐cause mortality (30 days post‐surgery) · people undergoing definitive fixation of hip, pelvic and long bone fractures
It is very uncertain whether topical tranexamic acid changes all‐cause mortality (30 days post‐surgery) compared with placebo (very low certainty).
1 finding from 1 review
Adverse effects · Adults with head and neck cancer undergoing curative or adjuvant radiotherapy (at risk of osteoradionecrosis of the jaws)
1 finding from 1 review
Adverse effects were an outcome of interest in the study conducting this comparison, however no mention was made of the presence or absence of any adverse events
1 study · 220 participants
Very low
Incidence of ORN · Adults with head and neck cancer undergoing curative or adjuvant radiotherapy (at risk of osteoradionecrosis of the jaws)
It is very uncertain whether hyperbaric oxygen therapy (HBO) following extractions changes incidence of ORN compared with perioperative antibiotic prophylaxis (penicillin G) following… (very low certainty).
1 finding from 1 review
Adverse effects · Adults with head and neck cancer undergoing curative or adjuvant radiotherapy (at risk of osteoradionecrosis of the jaws)
1 finding from 1 review
Adverse effects were an outcome of interest in the study conducting this comparison, however no mention was made of the presence or absence of any adverse events
1 study · 74 participants
Very low
Fracture · preventing bone disease in kidney transplant recipients
Bisphosphonate showed no clear difference in fracture compared with placebo or no treatment (low certainty).
1 finding from 1 review
Death (all causes) · preventing bone disease in kidney transplant recipients
It is very uncertain whether vitamin D changes death (all causes) compared with placebo or no treatment (very low certainty).
1 finding from 1 review
Cardiovascular mortality · preventing bone disease in kidney transplant recipients
It is very uncertain whether vitamin D changes cardiovascular death compared with placebo or no treatment (very low certainty).
1 finding from 1 review
Graft loss · preventing bone disease in kidney transplant recipients
It is very uncertain whether vitamin D changes graft loss compared with placebo or no treatment (very low certainty).
1 finding from 1 review